Unicycive Therapeutics, Inc. 8-K

What Happened

• On March 30, 2026, Unicycive Therapeutics, Inc. (UNCY) announced its financial results for the full year ended December 31, 2025 and provided a business update via a press release.
• The press release announcing the results and update is furnished as Exhibit 99.1 to the Form 8-K (filed under accession 0001213900-26-035961). The filing was made under Item 2.02 (Results of Operations and Financial Condition) and includes Inline XBRL cover page tags (Item 9.01).

Key Details

• Filing date: March 30, 2026.
• Reporting period: full year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Cover page XBRL tags embedded in the Inline XBRL document, per Item 9.01.

Why It Matters

• This filing is the company’s official disclosure of its 2025 financial performance and the latest business update; those details can affect investor assessments of revenue, expenses, cash runway, and program progress.
• Retail investors should read the Exhibit 99.1 press release (linked in the 8-K) to see the specific financial figures, operating results, and any management commentary or guidance referenced in the update.